120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
白癜风治疗的最新进展
Authors Qiu Y , Su X, Chen J, Jiang S, Tang X, He Y , Liu F
Received 29 October 2025
Accepted for publication 1 February 2026
Published 11 February 2026 Volume 2026:15 577653
DOI https://doi.org/10.2147/ITT.S577653
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Sarah Wheeler
Ye Qiu, Xiangxi Su, Jingru Chen, Shaojing Jiang, Xinrui Tang, Yurong He, Fang Liu
Department of Dermatology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, People’s Republic of China
Correspondence: Fang Liu, Department of Dermatology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, People’s Republic of China, Email roseliufang@qq.com
Purpose: This review systematically summarizes breakthrough advances in vitiligo treatment from 2020 to 2025 to provide the latest evidence-based insights for clinical practice.
Patients and Methods: We searched ClinicalTrials.gov and PubMed for literature and clinical trials published within this period. Inclusion criteria encompassed randomized controlled trials (RCTs), Phase II and above clinical trial results, and fundamental research with clear clinical translational value.
Results: Our analysis identified that JAK inhibitors achieved significant repigmentation by blocking the IFN-γ/JAK-STAT signaling pathway, while novel agents such as IL-15 inhibitors selectively eliminated pathogenic CD8⁺ T cells, suppressing immune-mediated damage at its source. The combination of 308 nm excimer laser with JAK inhibitors or platelet-rich plasma (PRP) increased repigmentation rates in acral lesions to 56.1%, and vitamin D adjunct therapy demonstrated synergistic effects. For stable disease, ReCell technology combined with narrowband UVB (NB-UVB) emerged as an effective option, whereas miniature punch grafting further optimized surgical outcomes. Additionally, repurposed traditional drugs and antioxidant strategies expanded the available clinical arsenal.
Conclusion: Vitiligo treatment has entered an era of precision immune modulation, with JAK inhibitors establishing themselves as first-line therapy and novel biologics showing significant promise. Combined phototherapy and cellular therapy innovations markedly enhance repigmentation efficiency, and drug repurposing continues to enrich the therapeutic landscape.
Keywords: vitiligo, targeted therapy, JAK inhibitors, IL-15 inhibitors, combined phototherapy
Department of Dermatology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, People’s Republic of China
Correspondence: Fang Liu, Department of Dermatology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, People’s Republic of China, Email roseliufang@qq.com
Purpose: This review systematically summarizes breakthrough advances in vitiligo treatment from 2020 to 2025 to provide the latest evidence-based insights for clinical practice.
Patients and Methods: We searched ClinicalTrials.gov and PubMed for literature and clinical trials published within this period. Inclusion criteria encompassed randomized controlled trials (RCTs), Phase II and above clinical trial results, and fundamental research with clear clinical translational value.
Results: Our analysis identified that JAK inhibitors achieved significant repigmentation by blocking the IFN-γ/JAK-STAT signaling pathway, while novel agents such as IL-15 inhibitors selectively eliminated pathogenic CD8⁺ T cells, suppressing immune-mediated damage at its source. The combination of 308 nm excimer laser with JAK inhibitors or platelet-rich plasma (PRP) increased repigmentation rates in acral lesions to 56.1%, and vitamin D adjunct therapy demonstrated synergistic effects. For stable disease, ReCell technology combined with narrowband UVB (NB-UVB) emerged as an effective option, whereas miniature punch grafting further optimized surgical outcomes. Additionally, repurposed traditional drugs and antioxidant strategies expanded the available clinical arsenal.
Conclusion: Vitiligo treatment has entered an era of precision immune modulation, with JAK inhibitors establishing themselves as first-line therapy and novel biologics showing significant promise. Combined phototherapy and cellular therapy innovations markedly enhance repigmentation efficiency, and drug repurposing continues to enrich the therapeutic landscape.
Keywords: vitiligo, targeted therapy, JAK inhibitors, IL-15 inhibitors, combined phototherapy